Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Current Deferred Revenue: 2017-2022

Historic Current Deferred Revenue for Summit Therapeutics (SMMT) over the last 5 years, with Jun 2022 value amounting to $3.2 million.

  • Summit Therapeutics' Current Deferred Revenue fell 54.75% to $3.2 million in Q2 2022 from the same period last year, while for Jun 2022 it was $3.2 million, marking a year-over-year decrease of 54.75%. This contributed to the annual value of $7.9 million for FY2021, which is 11.19% down from last year.
  • As of Q2 2022, Summit Therapeutics' Current Deferred Revenue stood at $3.2 million, which was down 36.61% from $5.1 million recorded in Q1 2022.
  • Summit Therapeutics' 5-year Current Deferred Revenue high stood at $8.9 million for Q4 2020, and its period low was -$35.9 million during Q2 2018.
  • For the 3-year period, Summit Therapeutics' Current Deferred Revenue averaged around $5.9 million, with its median value being $7.1 million (2021).
  • As far as peak fluctuations go, Summit Therapeutics' Current Deferred Revenue soared by 794.34% in 2021, and later slumped by 54.75% in 2022.
  • Over the past 5 years, Summit Therapeutics' Current Deferred Revenue (Quarterly) stood at -$8.0 million in 2018, then spiked by 92.95% to $2.6 million in 2019, then skyrocketed by 241.84% to $8.9 million in 2020, then dropped by 11.19% to $7.9 million in 2021, then slumped by 54.75% to $3.2 million in 2022.
  • Its Current Deferred Revenue stands at $3.2 million for Q2 2022, versus $5.1 million for Q1 2022 and $7.9 million for Q4 2021.